Scottish Medical Journal 22:241.[Web of Science ] , [Google Scholar])
The cost of cutting corners on expiration We understand the temptation
However, patients with palpable thyroid masses, unexplained weight loss, voice changes, or a strong personal or family history of medullary thyroid cancer should undergo thyroid imaging before starting semaglutide, per FDA guidance
FDA Crackdown on Compounded GLP-1s (Regulatory): On February 6, 2026, the FDA announced a formal intent to restrict the use of active pharmaceutical ingredients (APIs) for non-approved compounded GLP-1 drugs, targeting "mass-marketed" alternatives from companies like Hims & Hers as the national supply of brand-name versions stabilized
The views expressed by authors and contributors of such content are not endorsed or approved by Fay and are intended for informational purposes only